Discover 1,171 paid clinical trials in Dayton, Ohio. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,171
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety
for
Epileptic Encephalopathy, SCN2A Encephalopathy
Location: Cincinnati OH, Chicago IL, Memphis TN, Philadelphia PA,
Sponsor: Praxis Precision Medicines
Sex: All
Age: 0 - 18
Code: NCT07019922
Phase3, Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
for
Systemic Lupus Erythematosus
Location: Cincinnati OH, Columbus OH, Cleveland OH, Chicago IL,
Sponsor: AstraZeneca
Sex: All
Age: 5 - 17
Code: NCT05835310
Phase3, Recruiting
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia
for
Hyperkalaemia
Location: Cincinnati OH, Baltimore MD, Columbia SC, Birmingham AL,
Sponsor: AstraZeneca
Sex: All
Age: 0 - 18
Code: NCT03813407
Phase3, Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
for
Breast Cancer
Location: Cincinnati OH, Cleveland OH, Detroit MI, Chicago IL,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06103864
Phase3, Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
for
Chronic Kidney Disease and Hypertension
Location: Cincinnati OH, Columbus OH, Indianapolis IN, Canton OH,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06742723
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
for
Endometrial Cancer
Location: Cincinnati OH, Columbus OH, Ann Arbor MI, Pittsburgh PA,
Sponsor: AstraZeneca
Sex: Female
Age: 18+
Code: NCT06989112
Phase3, Recruiting
Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation